| Name | Title | Contact Details |
|---|
Icario is a health action company that frees you to help people live healthier lives by helping you connect with them like they`re human. With over 100 million+ member connections, Icario is a health action platform that unites pioneering technology, data science, and behavioral insights to connect everyone to better health. Our mission is to make the world a healthier place, one person at a time. In 2020, Revel + NovuHealth joined forces to create Icario because we knew we could do better together—creating value by uniting pioneering technology, data science, and behavioral insights to make the world a healthier place, one person at a time. There is an island in the Aegean Sea where people live extremely long lives. They`re happy, too. Families are close. They eat well. They exercise. And they stay connected with each other, and not just by smartphone. This got us thinking. What if we apply what we learn from the Blue Zone island of Ikaria (our namesake), add pioneering technology and exabytes of data, and help healthcare connect better with everyone? We`ll have a lot more healthy, happy people, and that`s a pretty good thing. As an organization, we`re a collaborative team of pioneers, inventors, and systems thinkers. We speak truth, are driven by data, and sweat the details. We`re a friendly and easygoing group, but we work hard because we are mission-driven, we know a better way, and we`re here to make it happen.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
4 Better Sleep is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.